Plant Name: Allium macrostemon
Taxonomic Information:
Plant ID: NPO4520
Plant Latin Name: Allium macrostemon
Taxonomy Genus: Allium
Taxonomy Family: Amaryllidaceae
Plant External Links:
NCBI TaxonomyDB:
91198
Plant-of-the-World-Online:
528368-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Astringent; Carminative; Depurative; Diuretic; Emmenagogue; Nervine; Tonic
Geographical Distribution:
Japan; China; Russia; Mongolia; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; HTR6; ADORA2A; ADORA1; | |
| TDP1; MIF; MTOR; TERT; ADK; | |
| TRPA1; | |
| GSK3B; | |
| MT-ND4; | |
| MAPT; PMP22; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MT-ND4 | NADH-ubiquinone oxidoreductase chain 4 | P03905 | CHEMBL4499 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.373E-08 | 5.166E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 5.687E-08 | 6.192E-04 | ADORA1, ADORA2A, ADORA3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 3.776E-07 | 2.741E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0051179; localization | GO:0044070; regulation of anion transport | 8.821E-07 | 3.842E-03 | ADORA1, ADORA2A, MIF, MTOR |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.459E-06 | 5.950E-03 | ADORA1, ADORA2A |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 9.454E-05 | 6.807E-03 | HTR6, ADORA2A, ADORA3, ADORA1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; HTR6; MAPT; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; GSK3B; MTOR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT; |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR6; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MTOR; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; TRPA1; MTOR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; MTOR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR; |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; |
| NA: NA | Coronary artery restenosis | NA | MTOR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; GSK3B; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; MAPT; GSK3B; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
